Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

Blood (2023) 142 (Supplement 1): 3074.

https://doi.org/10.1182/blood-2023-184933

Published: 2023

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Blood (2022) 140 (Supplement 1): 9375–9377.

https://doi.org/10.1182/blood-2022-159949

Published: 2022

Journal Articles

Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs

Blood (2022) 140 (Supplement 1): 10720–10721.

https://doi.org/10.1182/blood-2022-158808

Published: 2022

Journal Articles

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Antonella Anastasia, Chiara Pagani, Alessandro Re, Marina Motta, Giacomo Pata, Enrico Damiani, Lisa Gandolfi, Rosa Daffini, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 11951–11953.

https://doi.org/10.1182/blood-2022-164792

Published: 2022

Journal Articles

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Blood (2022) 140 (17): 1907–1916.

https://doi.org/10.1182/blood.2022015560

Published: 2022

Includes: Supplemental data

Journal Articles

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Erika Borlenghi, Diego Bertoli, Chiara Cattaneo, Margherita Sciumé, Elisa Cerqui, Chiara Pagani, Nicola Bianchetti, Margherita Oberti, Rossella Leopaldo, Cecilia Carbone, Silvana Archetti, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2021-149719

Published: 2021

Journal Articles

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

Chiara Pagani, Chiara Rusconi, Alessia Dalla Pria, Emanuele Ravano, Philipp Schommers, Mariana Bastos-Oreiro, Luisa Verga, Guido Gini, Michele Spina, Luca Arcaini, Sara Steffanoni, Davide Dalu, Chiara Cattaneo, Fabio Facchetti, Giuseppe Rossi, Alessandra Tucci, Alessandro Re

Blood (2021) 138 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2021-151149

Published: 2021

Journal Articles

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 2496.

https://doi.org/10.1182/blood-2021-149649

Published: 2021

Journal Articles

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Alessandra Tucci, MD, Alessandro Re, MD, Chiara Pagani, MD, Anna Guidetti, Anna Dodero, Fabrizio Marino, MD, Ivana Casaroli, MD, Giulia Soverini, MD, Rosa Daffini, MD, Monica Balzarotti, Giulia Campostrini, Luisa Lorenzi, MD, Piera Balzarini, Fabio Facchetti, Carmelo Carlo-Stella, MD, Paolo Corradini, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-139977

Published: 2020

Journal Articles

Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Chiara Cattaneo, Valeria Cancelli, MD, Chiara Pagani, MD, Alessandra Tucci, MD, Giuseppe Rossi, MD, Luisa Imberti, MD, Alessandra Sottini, BS, Kerry Dobbs, BS, Elana Shaw, BS, Luigi D. Notarangelo, MD, Jeffrey Cohen, MD, Peter Burbelo, PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-141355

Published: 2020

Journal Articles

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Samantha Ferrari, MD, Chiara Pagani, MD, Mariella D'Adda, MD, Nicola Bianchetti, MD, Annamaria Pelizzari, MD, Doriana Gramegna, MD, Chiara Bottelli, MD, Luisa Lorenzi, MD, Gabriella Vona, Alessandra Tucci, MD, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139431

Published: 2020

Journal Articles

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, MD, Massimo Bernardi, MD, Valentina Mancini, MD, Chiara Pagani, MD, Monica Fumagalli, MD, Patrizia Zappasodi, MD, Erika Borlenghi, MD, Alessandro Re, MD, Fabio Ciceri, MD, Margherita Sciumé, Roberto Cairoli, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 3603.

https://doi.org/10.1182/blood-2019-125288

Published: 2019

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study

Blood (2018) 132 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2018-99-113772

Published: 2018

Journal Articles

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Alessandro Re, MD, Nicola Bianchetti, Chiara Cattaneo, MD, Salvatore Casari, MD, Chiara Pagani, MD, Annalisa Peli, MD, Emanuele Focà, MD, Pierino ferremi Leali, MD, Camillo Almici, MD, Francesco Castelli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2018-99-116816

Published: 2018

Journal Articles

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Nicola Bianchetti, Alessandra Tucci, Alessandro Re, MD, Chiara Pagani, MD, Chiara Cattaneo, MD, Maria Miscio, Fabio Facchetti, Simona Fisogni, MD, Piera Balzarini, Domenico Albano, Giovanni Bosio, Francesco Bertagna, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 4232.

https://doi.org/10.1182/blood-2018-99-119090

Published: 2018

Journal Articles

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

Chiara Cattaneo, MD, Doriana Gramegna, Chiara Pagani, MD, Erika Borlenghi, Michele Malagola, MD, Elisa Cerqui, MD, Angela Passi, MD, Francesca Schieppati, MD, Claudia Crippa, MD, Daniela Dalceggio, Cecilia Carbone, MD, Anna Maria Pelizzari, Margherita Sciumé, Alessandro Re, MD, Domenico Russo, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 2288.

https://doi.org/10.1182/blood.V130.Suppl_1.2288.2288

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

NARROW

PET4 Response As an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse

Adverse Prognostic Role of IDH2 Mutations at Diagnosis and during Follow-up in Patients with Acute Myeloid Leukemia and Normal Karyotype

Do MYC Alterations Matter in HIV-Associated Large B Cell Lymphomas? the "Euromyc" Study (a European retrospective study)

A Simplified Geriatric Assessment (sGA) Can Identify Older Patients with Relapse/Refractory (R/R) Aggressive Lymphoma Suitable for Autologous Stem Cell Transplantation (ASCT): Final Results of Recanz Multicentre Prospective Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number

Longitudinal Serological Response to Sars-COV-2 in Patients Affected By Hematologic Diseases

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Acute Leukemia and High-Risk Myelodysplastic Syndromes in HIV-Positive Patients: 25-Years' Experience of the Rete Ematologica Lombarda (REL)

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Isavuconazole in Hematological Patients: Results of a Real-Life Multicenter Seifem Study

Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype

Very Poor Outcome of Patients with Relapsed/Refractory Aggressive B Cell Lymphoma after Autologous Stem Cell Transplantation (ASCT) or High Dose of Methotrexate and Cytarabine (HD-MTX/ARA-C) Regimens in the Clinical Care Setting

Invasive Pulmonary Aspergillosis in Acute Leukemia in the Era of New Antifungal Treatment and Prophylaxis Is Still Frequent, Even in Patients with Acute Lymphoblastic Leukemia, and Adversely Affects the Overall Treatment Outcome. Results of a 5-Year Study at a Single Institution

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only